Skip Navigation

Expanding the Reach of Precision Cancer MedicinesPioneering the Development of Novel MasterKey Therapies

Pioneering the Development of Novel MasterKey Therapies

Black Diamond is addressing the significant unmet need for novel precision oncology therapies for patients with genetically defined cancers who have limited treatment options. Black Diamond is built upon a deep understanding of cancer genetics, onco-protein function and drug discovery.

The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, aggregate these mutations into families, de-orphaning oncogenic mutations and develop a single spectrum-selective therapy in a MasterKey manner that targets a specific family of mutations.

In Memoriam

We share our sincerest condolences on the passing of our former colleague and Chairman of our Board from 2020-2022, Robert "Bob" Ingram. We are deeply saddened by Bob’s passing, and we will be forever grateful for his numerous contributions and impact both on the industry and at Black Diamond. Working alongside many of Black Diamond’s founders, Bob was a steadfast and greatly respected colleague, leader, gentleman and friend. Bob Ingram will be greatly missed.